• Events & presentations
GenSight Biologics will present 5 posters related to both clinical-stage product candidates at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaï. Pr. José-Alain Sahel will present GS010 Phase I/II 1.5 years published results and REVERSE Phase III topline data at the 5th Annual Retinal Cell and Gene Therapy Innovation Summit taking place just prior to the ARVO.

GS010 – Leber’s Hereditary Optic Neuropathy (LHON) 

Oral Presentation Title:  Gene Therapy for Leber Hereditary Optic Neuropathy, 18-month Results from a Phase Ib-IIa Trial

5th Annual Retinal Cell and Gene Therapy Innovation Summit

  • Session 4: Gene Therapy II
  • Session Date/Times:  Friday, April 27, 2018, 4:40 – 4:55 pm

Poster presentation Title:  Baseline Structural and Psychophysical Profiles of Subjects Enrolled in Phase 3 Trials with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON

  • Presentation number – Posterboard Number: 3901 – C0367
  • Session Number:  LV, VI
  • Session Title:  Profound Low Vision and Low-vision Clinical Trials
  • Session Date/Times:  Tuesday, May 1, 2018 from 3:30 PM to 5:15 PM

Poster Presentation Title: Visual Acuity and Safety Outcomes 2.5 Years Post-Treatment with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON: Results of a Phase I/II Trial

  • Presentation Number – Posterboard Number: 4530 – A0045
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times:  Wednesday, May 2, 2018 from 11:15 AM to 1:00 PM

Poster Presentation Title: Impact of sequential bilateral intravitreal injection of rAAV2/2-ND4 on ocular and systemic humoral immune status in non-human primates

  • Presentation Number – Posterboard Number: 4537 – A0052
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times:  Wednesday, May 2, 2018 from 11:15 AM to 1:00 PM

Poster Presentation Title: Intravitreal injection of rAAV2/2-ND4 in LHON: absence of correlation between ocular inflammation and humoral or cellular immune responses to AAV2

  • Presentation Number – Posterboard Number: 4531 – A0046
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times:  Wednesday, May 2, 2018 from 11:15 AM to 1:00 PM

GS030 – Optogenetics in Retinitis Pigmentosa (RP) 

Poster Presentation Title: Ocular Safety of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) following intravitreous injection and exposure to 595 nm LED light in blind rd1 mice

  • Presentation Number – Posterboard Number: 5658 – A0377
  • Session Number: 515
  • Session Title: Gene therapy, implants
  • Session Date/Times:  Thursday, May 3, 2018 from 8:15 AM to 10:00 AM